Peptide Synthesis Market

Peptide Synthesis Market

Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method (Chemical Synthesis and Non-Chemical Synthesis), Type of Chemical Synthesis (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis and Hybrid Phase Peptide Synthesis), Contract Manufacturing Organization Size (Small, Mid-sized, and Large Companies), Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World)The peptide synthesis market is expected to reach USD 2.5 billion by 2023 anticipated to grow at a CAGR of 5.46% during the forecast period 2023-2035.

Peptides function as signaling molecules that bind to specific receptors on cell surfaces, initiating intracellular effects that regulate physiological functions and metabolic synthesis of various components. Their significance as potential therapeutics has increased due to improved metabolic stability, target specificity, and affinity. Unlike small molecule drugs and biologics, peptide-based therapeutics pose unique challenges in pharmacological research, analytical/process development, impurity research, and structure recognition. The peptide synthesis market has undergone significant evolution recently, driven by the rising popularity of peptide therapeutics. Currently, more than 80 peptide therapeutics have received global approval for treating various chronic diseases such as cancer, chronic pain, diabetes, HIV infection, multiple sclerosis, and osteoporosis. Additionally, since 2015, over 630 clinical trials have been conducted to assess the therapeutic efficacy of peptide-based therapies. Furthermore, increased research activity and demand for peptide-based treatments have prompted developers to enhance their capabilities and upgrade manufacturing equipment. However, peptide synthesis encounters challenges such as production capacity shortages, leading developers to outsource complex manufacturing processes to contract service providers to reduce costs and time to market. Pharmaceutical and biotechnology firms are actively partnering with contract manufacturing organizations (CMOs) offering advanced technology platforms to improve the bioavailability of peptide drugs and enhance synthesis efficacy. The demand for outsourcing surged with the introduction of semaglutide generics into the peptide synthesis market. Notably, the demand for GLP-1 peptide API contract manufacturing increased significantly at an annual rate of 37% during 2017-2023 due to its benefits in treating metabolic disorders like type II diabetes and obesity. These factors present promising opportunities for contract manufacturers in the peptide synthesis market in the foreseeable future.Report Coverage

The report comprehensively examines the peptide synthesis market based on type of synthesis method used, type of chemical synthesis method, company (CMO) size and key geographical regions.

It thoroughly analyzes market influences such as drivers, restraints, opportunities, and challenges, while evaluating competitive landscapes for top players. Forecasts are provided for segment revenues across major regions.

An extensive assessment of the current market landscape of contract manufacturers offering peptide synthesis services, covering various relevant parameters such as establishment year, entry year into peptide API manufacturing, company size (employee count), headquarters location, product type (API, intermediates, FDF / fill-finish), API type, services provided, peptide synthesis method, peptide modification type, purification technology, regulatory certifications, geographical presence, and location of peptide API manufacturing facilities.

Detailed evaluation of the competitiveness of peptide synthesis contract manufacturers, considering supplier strength and company competitiveness regarding API type, service offering, synthesis method, purification technique, operational scale, and geographical presence. Additionally, the number of peptide modification services offered is also taken into account. This evaluation includes a comprehensive review of recent developments and initiatives undertaken by contract manufacturers in the peptide synthesis industry, focusing on partnerships, collaborations, and expansion initiatives from 2014 to October 2023.

In-depth analysis of ongoing and planned studies focused on peptide therapeutics, covering various parameters such as trial registration year, number of enrolled patients, trial phase, status, study design, sponsor/collaborator type, therapeutic area, mechanism of action, clinical trial centers, geography, and patient population.

Detailed examination of the capabilities of peptide synthesis companies in different regions, considering parameters like the number of Contract Manufacturing Organizations (CMOs), clinical sites, clinical trials, enrolled patients, peptide manufacturing facilities, demand for peptide therapeutics, and installed capacity.

Informed estimates of the annual commercial and clinical demand for peptide therapeutics based on parameters such as target patient population, dosing frequency, and dose strength.

Estimate of the global installed capacity of contract manufacturers in the peptide synthesis market, considering data reported by industry stakeholders and factoring in the distribution of peptide production capacity among companies of different sizes (small, mid-sized, and large), operational scale (preclinical/clinical and commercial), location of manufacturing facility (North America, Europe, and Asia Pacific), and synthesis method (solid phase peptide synthesis and liquid phase peptide synthesis).

Analysis highlighting potential strategic partners based on the likelihood of collaborating with peptide therapeutics developers, shortlisted considering parameters like pipeline strength, pipeline maturity, year of establishment, and company size.

Qualitative examination outlining the key factors that peptide drug developers must consider when deciding whether to produce their products in-house or engage the services of a Contract Manufacturing Organization (CMO).

In-depth, region-specific analysis of the total cost of ownership associated with engaging a peptide contract manufacturing service provider, providing an estimate of both direct and indirect expenses across 10 relevant parameters over a 20-year timeframe.

Review of regulatory guidelines concerning peptide synthesis, focusing on variations observed across different regions such as the US, Europe, Australia, China, India, Japan, and South Korea. This discussion also addresses the regulatory challenges faced by peptide synthesis companies.

Discussion on industry-related trends, key drivers, and challenges within the peptide synthesis sector, structured within a SWOT framework, including a Harvey ball assessment to highlight the relative impact of each SWOT parameter on industry dynamics.

Key Market Companies

AmbioPharm

CPC Scientific

Creative Peptides

CSBio

Bachem

BCN Peptide

CordenPharma

Senn Chemicals

PolyPeptide

Auspep

Chinese Peptide Company

Hybio Pharmaceuticals

Peptide Institute

ScinoPharm